Autobio Diagnostics Co., Ltd.
603658
Rangering i aksjer
#4904
Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical... Autobio Diagnostics Co., Ltd. specializes in the full lifecycle of clinical diagnostic products, from their initial research and development to manufacturing and market distribution. Their diverse offerings encompass a range of reagents for immunoassay, biochemistry, microbiology, and in-vitro diagnostics (IVD). Additionally, they provide advanced automated and semi-automated instrumentation, alongside comprehensive medical laboratory solutions. Notable immunoassay products include the AutoLumo A2000 Plus automatic chemiluminescence immunoassay analyzer, automated microplate chemiluminescent enzyme immunoassays, LUmo luminometers, PHOmo microplate readers, and iWO microplate washers. Within their microbiology division, they offer automated blood culture systems, blood culture bottles, AUTOMIC strips, and mycoplasma IES. Founded in 1998, the company originally operated as Lifeclone Diagnostics Co., Ltd. before adopting its current name, Autobio Diagnostics Co., Ltd., in 2003. Headquartered in Zhengzhou, China, it functions as a subsidiary of Zhengzhou Auto Industrial Co., Ltd.
Aksjekurs
$5.15
Sist synkronisert: 2026-10-22
Markedsverdi
$2.94B
Endring (1 dag)
0.97%
Endring (1 år)
-5.80%
Land
CN
Handel Autobio Diagnostics Co., Ltd. (603658)
Kategori
Healthcare
Antall utestående aksjer for Autobio Diagnostics Co., Ltd. (603658)
Antall utestående aksjer per June 2026: 571.42M
Ifølge Autobio Diagnostics Co., Ltd. sine siste økonomiske rapporter og aksjekurs er antall utestående aksjer nå 571.42M. Ved slutten av December 2024 hadde selskapet 577.03M utestående aksjer. Antallet utestående aksjer påvirkes vanligvis av aksjesplitt og tilbakekjøp.
Historikk over utestående aksjer for Autobio Diagnostics Co., Ltd. (603658) fra 2011 til 2026
Utestående aksjer ved utgangen av hvert år
| År | Utestående aksjer | Endre |
|---|---|---|
| 2026 (TTM) | 571.42M | 0.05% |
| 2025 | 571.13M | -1.02% |
| 2024 | 577.03M | -0.47% |
| 2023 | 579.73M | -0.68% |
| 2022 | 583.72M | -0.44% |
| 2021 | 586.27M | 5.06% |
| 2020 | 558.06M | 2.21% |
| 2019 | 546.00M | 0.04% |
| 2018 | 545.76M | -0.04% |
| 2017 | 546.00M | 6.87% |
| 2016 | 510.88M | 4.60% |
| 2015 | 488.43M | -0.75% |
| 2014 | 492.13M | 0.69% |
| 2013 | 488.78M | -2.21% |
| 2012 | 499.84M | -14.74% |
| 2011 | 586.27M | 0.00% |
Utestående aksjer for lignende selskaper eller konkurrenter
| Selskap | Utestående aksjer | Forskjell | Land |
|---|---|---|---|
| 370.00M | -35.25% |
US
|
|
| 703.80M | 23.17% |
US
|
|
| 143.28M | -74.93% |
US
|
|
| 2.91B | 409.06% |
CN
|
|
| 282.00M | -50.65% |
US
|
